Myo-Inositol PCOS Pregnancy Complications JAMA 2025: No Effect on Gestational Diabetes or Preeclampsia
Myo-inositol, a core option in the polycystic ovary syndrome (PCOS) supplement market, shows no effect over placebo for pregnancy complication prevention. The JAMA 2025 multicenter randomized trial publishing a clear negative result redraws the indication boundary of myo-inositol.
MYPP trial core results
Participants: PCOS pregnant women recruited at 13 hospitals in the Netherlands (2019~2023).
Intervention: Myo-inositol supplementation or placebo. During pregnancy.
Composite primary endpoint: Gestational diabetes, preeclampsia, preterm birth.
Result: No statistically significant difference vs placebo.
Interpretation: Myo-inositol monotherapy not recommended for pregnancy complication prevention targeting.
Non-pregnant PCOS effect differs
Insulin resistance improvement: Meaningfully improved in meta-analyses.
Ovarian function: Some data on ovulation restoration.
Metabolic markers: Some improvements in glucose, insulin, androgens.
ART (assisted reproductive technology) outcomes: Some trials improved embryo quality, pregnancy rates. Mixed meta-analysis data.
Lifestyle + myo-inositol: Adjunct effect on the foundation of diet + exercise.
SOGC position statement (2025)
Society of Obstetricians and Gynaecologists of Canada published position statement on inositol use in PCOS management. Core message: metabolic/ovarian adjunct option in non-pregnant PCOS. Insufficient effect for pregnancy complication prevention.
What is myo-inositol
Inositol: 9 isomers. Myo-inositol most common.
D-chiro-inositol (DCI): Another isomer. Common 40:1 ratio combination with myo-inositol in PCOS.
Role: Aids insulin receptor signaling, ovarian hormone signaling.
Dietary sources: Rich in fruits, beans, grains. Bananas, beans, corn etc.
Standard supplement dose: Myo-inositol 2~4 g/day. With DCI or alone.
Mechanism
Insulin signaling improvement: Aids post-insulin receptor signaling. Slows insulin resistance.
Ovarian hormone signaling: Aids FSH, LH balance. Restores ovulation.
Androgen reduction: Some trials reduce testosterone.
Metabolic markers: Some improvements in glucose, lipids.
Egg quality: Some trials improve ART outcomes.
Position in PCOS matrix
Layer 1 — foundation: Weight management (5~10% reduction), diet (low glycemic load), exercise.
Layer 2 — prescriptions: Metformin (insulin resistance), oral contraceptives (androgens), clomiphene/letrozole (infertility).
Layer 3 — supplements: Myo-inositol + DCI (2~4 g/day), vitamin D (if deficient), omega-3.
Layer 4 — pregnancy targeting: With ART. Physician evaluation.
Who fits
PCOS metabolic targeting (non-pregnant): Insulin resistance, glucose adjunct.
PCOS ovarian function targeting: Ovulation restoration adjunct. Physician evaluation.
ART adjunct: Some clinical data. Physician evaluation.
Metformin side effects: Option for populations difficult to use metformin due to side effects. Consult a clinician.
Who should be careful
Pregnancy complication prevention monotherapy: Insufficient effect. Only as part of matrix.
Type 1 diabetes: Limited data.
Thyroid disease: Possible some effects. Consult a clinician.
Drug interactions: Caution with insulin medications. Consult a clinician.
GI sensitivity: Take split with meals.
Daily guide
Step 1 — diagnosis: Physician evaluation. Hormone panel, insulin, glucose, lipids, thyroid.
Step 2 — foundation: Weight management, low glycemic load diet, exercise 150+ min/week.
Step 3 — prescription review: Metformin, oral contraceptive, infertility drug indication evaluation.
Step 4 — myo-inositol: 2~4 g/day (DCI 40:1 combination or alone). Split with meals.
Step 5 — pregnancy targeting: After physician evaluation. Myo-inositol alone insufficient for pregnancy complication prevention.
Step 6 — monitoring: Hormone, metabolic re-test at 3~6 months.
Myo-inositol is one tool of the PCOS matrix. Effect validated for non-pregnant metabolic targeting; insufficient effect for pregnancy complication prevention. Use with awareness of effect differences by target.